Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 12-Week lifestyle program slash heart risk in families?

NCT ID NCT00552591

Prevention Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests whether a 12-week program led by a heart health educator can lower cholesterol and improve heart health in spouses, siblings, and children of people hospitalized with coronary heart disease. Participants work with an educator to create a personal plan for smoking cessation, exercise, healthy eating, and weight management, with medication support if needed. The goal is to see if this targeted approach reduces the ratio of total to HDL cholesterol and other risk factors compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
12-week risk reduction program with heart health educator
What this could lead to
If effective, this program could offer a simple, low-cost way to help families of heart patients lower their own heart disease risk through lifestyle changes and medication support.
What could go wrong
This is a single-center trial with 426 participants, so results may not apply to all populations. The program relies on personal motivation, and long-term adherence is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

426 people

The number who actually took part.

Start date

Sep 2007

Finished

Sep 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Spouse, offspring or sibling of patient hospitalized at UOHI within the past 5 years for: 1. Acute coronary syndrome (ACS); 2. Elective percutaneous coronary intervention (PCI); or 3. Bypass surgery (CABG); * Willing to provide informed consent; * At least one of the following modifiable risk factors: 1. Current smoker; 2. Systolic blood pressure ≥ 140 and or Diastolic BP ≥ 90 and/or currently on medication to treat high blood pressure; 3. Total cholesterol/HDL-cholesterol ratio ≥ 5.0 and/or on antilipemic medication; 4. Abdominal obesity (for men, waist circumference \> 102 cm; for women, waist circumference \> 88cm); 5. Physical Inactivity \[\<150 min mod, 5-7 d/week or \<100 min vig, 4-7 d/week\] * Geographically available for assessment, intervention and follow-up. Exclusion Criteria: 1. Unable to understand English or French; 2. History of diabetes mellitus or any atherosclerotic disease; 3. Fasting glucose ≥ 7.0 mmol/L at screening; 4. Presence of life threatening illness (e.g., known or suspected cancer or other disease with a life expectancy of less than five years); 5. Chronic kidney disease and/or undergoing dialysis; 6. Active liver disease; 7. Pregnant or planning to become pregnant within the next year; 8. Cognitive impairment; 9. Other family member already participating in study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary heart disease

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.